Glaucoma

Glaucoma is the second leading cause of blindness, and since most cases of glaucoma have no pain and no symptoms, it is important to be screened for it every year. Glaucoma is an eye disease usually associated with an increase in the intraocular pressure (pressure inside the eyes), which leads to damage to the optic nerve. If untreated it can progress, causing irreversible damage which can lead to blindness.

The main types of glaucoma are open angle glaucoma and acute closed angle glaucoma. Open angle glaucoma is a chronic, usually slow progressing disease. It gradually reduces your peripheral vision until tunnel vision is all that’s left. It can be treated with eye drops or surgery. Acute closed angle glaucoma produces sudden symptoms like eye pain, headaches, halos around lights, nausea, red eyes and vision loss, which usually lasts for a few hours. Each attack causes more vision loss. It’s normally treated surgically.

Glaucoma is screened for using tonometry, visual fields, and an evaluation of your optic nerve. Tonometry is a measurement of the pressure inside the eyes. Visual field testing maps out any blind spots in your vision. Your optic nerve is best evaluated using a retinal photo  or thru a dilated pupil.

For more information check   http://www.glaucoma.org/

Vision News

  • Alcon Launches AcrySof(R) IQ ReSTOR(R) Toric Intraocular Lens Outside The United States
  • Starting The School Year Right
  • Drug Discovery Tools To Fight Cancer, Blindness To Be Discussed At UB Symposium
  • 'Back-To-School' How To Prevent Sports Related Eye Injuries
  • Carl Zeiss Meditec Is Shaping The Future Of Ophthalmology: Creating What's To Come
  • OptiMedica's Laser Cataract Surgery System To Be Featured In Three Clinical Presentations At ESCRS 2010
  • Dr. Tom Tooma Purchases Interest In All 12 Southern California TLC Laser Eye Centers, Changing Name To NVISION Laser Eye Centers
  • Bausch + Lomb Releases Single-Use Vitreoretinal Asymmetric Peeling Forceps
  • New Data Will Help Predict Vision Loss In Glaucoma
  • Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
  • ReVision's Fenretinide (RT-101) Reduced Incidence Of Choroidal Neovascularization By More Than 50 Percent In Patients With Geographic Atrophy
  • Microplasmin Meets Primary Endpoint In Second Phase III Trial In VMA, Confirms Positive Findings Of First Trial
  • pSivida Announces Iluvien(R) Receives FDA Priority Review For Treatment Of Diabetic Macular Edema
  • Allergan Receives FDA Approval For LUMIGAN(R) 0.01% As First-Line Therapy Indicated For The Reduction Of Elevated Intraocular Pressure In Glaucoma
  • Improving Ocular Disease Screening By LED Illumination Of The Eye
  • Eyegenix™ Artificial Cornea Achieves Major Advancement Towards Curing Corneal Blindness
  • Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review
  • Optometrists Encourage Eye Test For Children, Ireland
  • 'Toolbox Of MiniPromoters' For Gene Research And Therapy Unvelied By UBC Researchers
  • Revolutionary Way To Treat Eye Cancer May Prevent Blindness
  • More...